Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 6/20 | 0.44 |
| ▸ | NMT2 | O60551 | 5/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.39 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.36 |
| ▸ | FURIN | P09958 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31754320 | 0.89 | TLR2 (0.43) | NMT1NMT2TLR2TERTPTGS1 | |
| SCHEMBL30398536 | 0.88 | QRFPR (0.42) | NMT1NMT2TLR2QRFPRROCK2 | |
| SCHEMBL8766612 | 0.88 | TERT (0.49) | TLR2TERTPTGS1GSTK1 | |
| SCHEMBL30445612 | 0.84 | NMT1 (0.49) | NMT1NMT2TLR2TERT | |
| SCHEMBL30788344 | 0.84 | PTGS1 (0.50) | NMT1NMT2TLR2PTGS1GSTK1 | |
| SCHEMBL29895299 | 0.82 | NMT1 (0.49) | NMT1NMT2TLR2TERT | |
| SCHEMBL30788335 | 0.82 | PTGS1 (0.51) | NMT1NMT2TLR2PTGS1GSTK1 | |
| SCHEMBL30398684 | 0.82 | NMT1 (0.46) | NMT1NMT2TLR2UTS2R | |
| SCHEMBL30828464 | 0.81 | FOLH1 (0.48) | NMT1NMT2TERTPTGS1GSTK1 | |
| SCHEMBL30626179 | 0.81 | TLR2 (0.47) | NMT1NMT2TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814416-B2 | Polypeptide capable of passing through blood-brain barrier | SHENZHEN RUIJIAN BIOSCIENCE TECHNOLOGY LIMITED COMPANY (CN) | 2023-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814416-B2 | Polypeptide capable of passing through blood-brain barrier | VIP, NGLY1, PGF | NMT1 162/4885NMT2 308/4885TLR2 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.